Immunopathology & Immunotherapy

Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy in which the patient’s own T cells are isolated in the laboratory, redirected with a synthetic receptor to recognize a particular antigen or protein, and reinfused into the patient. Clinical trials of CAR T cells directed to the CD19 antigen have shown impressive results in advanced B-cell malignancies at multiple academic centers over the last 3 years. We describe the technology of CAR T cells, findings at 5 academic centers, and toxicities associated with CAR T cell-treatment and their management. Although CAR T cells for B-cell malignancies are the most advanced in terms of clinical testing, CAR T cells are the basis of a new platform technology that is poised to be expanded to other hematologic and nonhematologic malignancies, especially as new targets are identified and manufacturing processes are streamlined.
  - See more at: http://www.onclive.com/publications/contemporary-oncology/2014/August-2014/Chimeric-Antigen-Receptor-CAR-T-Cell-Immunotherapy-for-Leukemia-and-Beyond?__scoop_post=3c482f60-3053-11e4-b39b-842b2b775358&__scoop_topic=827181#__scoop_post=3c482f60-3053-11e4-b39b-842b2b775358&__scoop_topic=827181